Participants
Contact
Research performed by Fernando Albericio, at IRB Barcelona, and PharmaMar is the focus of the article entitled "De la ciencia al mercado" (From the lab bench to the market), published in the newspaper “La Vanguardia”. The journalist explains the scientific breakthrough of synthesizing, in a lab, a natural compound such Thiocorlaine, a substance with anti-tumour properties discovered by the biotech company.
Read the news in La Vanguardia (PDF in Spanish)
Link to La Vanguardia
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
